CoChat

Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference

Open access
McCudden, Christopher, Axel, Amy E., Slaets, Dominique, Dejoie, Thomas, Clemens, Pamela L., Frans, Sandy, Bald, Jaime, Plesner, Torben, Jacobs, Joannes F.M., van de Donk, Niels W.C.J., Moreau, Philippe, Schecter, Jordan M., Ahmadi, Tahamtan, Sasser, A. Kate · 2016 · Clinical Chemistry and Laboratory Medicine (CCLM)
Cited by 124

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Monoclonal antibodies are promising anti-myeloma treatments. As immunoglobulins, monoclonal antibodies have the potential to be identified by serum protein electrophoresis (SPE) and immunofixation electrophoresis (IFE). Therapeutic antibody interference with standard clinical SPE and IFE can confound the use of these tests for response assessment in clinical trials and disease monitoring. To discriminate between endogenous myeloma protein and daratumumab, a daratumumab-specific immunofixation electrophoresis reflex assay (DIRA) was developed using a mouse anti-daratumumab antibody. To evaluate whether anti-daratumumab bound to and shifted the migration pattern of daratumumab, it was spiked into daratumumab-containing serum and resolved by IFE/SPE. The presence (DIRA positive) or absence (DIRA negative) of residual M-protein in daratumumab-treated patient samples was evaluated using predetermined assessment criteria. DIRA was evaluated for specificity, limit of sensitivity, and reproducibility. In all of the tested samples, DIRA distinguished between daratumumab and residual M-protein in commercial serum samples spiked with daratumumab and in daratumumab-treated patient samples. The DIRA limit of sensitivity was 0.2 g/L daratumumab, using spiking experiments. Results from DIRA were reproducible over multiple days, operators, and assays. The anti-daratumumab antibody was highly specific for daratumumab and did not shift endogenous M-protein. As the treatment of myeloma evolves to incorporate novel monoclonal antibodies, additional solutions will be needed for clinical monitoring of patient responses to therapeutic regimens. In the interim, assays such as DIRA can inform clinical outcomes by distinguishing daratumumab from endogenous M-protein by IFE.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1515/cclm-2015-1031

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 34

  1. 2014, Development of clinical assay to mitigate daratumumab, an IgG1k monoclonal antibody, interference with serum immunofixation (IFE) and clinical assessment of M-protein response in multiple myeloma, Cancer Res, 74
  2. 2012, Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking, Blood, 120
  3. 2015, Immunomodulatory effects and adaptive immune response to daratumumab in multiple myeloma, Blood, 126
  4. 2016, Daratumumab: first global approval, Drugs, 76, 275, 10.1007/s40265-015-0536-1 · DOI · Paper page
  5. 2005, International staging system for multiple myeloma, J Clin Oncol, 23, 3412, 10.1200/JCO.2005.04.242 · DOI · Paper page
  6. 2009, Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma, Leukemia, 23, 3, 10.1038/leu.2008.291 · DOI · Paper page
  7. 2015, Targeting CD38 with daratumumab monotherapy in multiple myeloma, N Engl J Med, 373, 1207, 10.1056/NEJMoa1506348 · DOI · Paper page
  8. Elotuzumab: serum protein electrophoresis and immunofixation interference with clinical assessment of M-protein response in relapsed/refractory multiple myeloma (RRMM)
  9. 2015, Elotuzumab therapy for relapsed or refractory multiple myeloma, N Engl J Med, 373, 621, 10.1056/NEJMoa1505654 · DOI · Paper page
  10. 2005, International staging system for multiple myeloma, J Clin Oncol, 23, 3412, 10.1200/JCO.2005.04.242 · DOI · Paper page
  11. 2011, Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1, Blood, 117, 4691, 10.1182/blood-2010-10-299487 · DOI · Paper page
  12. 2015, Immunomodulatory effects and adaptive immune response to daratumumab in multiple myeloma, Blood, 126
  13. 2014, Development of clinical assay to mitigate daratumumab, an IgG1k monoclonal antibody, interference with serum immunofixation (IFE) and clinical assessment of M-protein response in multiple myeloma, Cancer Res, 74
  14. 2016, Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial, Lancet
  15. 2013, Evaluation of digital images for identification and characterization of monoclonal immunoglobulins by immunofixation, Clin Biochem, 46, 255, 10.1016/j.clinbiochem.2012.10.030 · DOI
  16. 2011, Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors, J Immunol, 186, 1840, 10.4049/jimmunol.1003032 · DOI · Paper page
  17. 2013, Evaluation of digital images for identification and characterization of monoclonal immunoglobulins by immunofixation, Clin Biochem, 46, 255, 10.1016/j.clinbiochem.2012.10.030 · DOI
  18. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79
  19. 2006, International uniform response criteria for multiple myeloma, Leukemia, 20, 1467, 10.1038/sj.leu.2404284 · DOI · Paper page
  20. 2015, Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma, MAbs, 7, 311, 10.1080/19420862.2015.1007813 · DOI · Paper page
  21. 2015, Assessing clinical response in multiple myeloma (MM) patients treated with monoclonal antibodies (mAbs): validation of a daratumumab IFE reflex assay (DIRA) to distinguish malignant M-protein from therapeutic antibody, J Clin Oncol, 33
  22. 1998, Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation, Blood, 91, 3518, 10.1182/blood.V91.9.3518 · DOI
  23. 2012, Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking, Blood, 120
  24. 2015, Assessing clinical response in multiple myeloma (MM) patients treated with monoclonal antibodies (mAbs): validation of a daratumumab IFE reflex assay (DIRA) to distinguish malignant M-protein from therapeutic antibody, J Clin Oncol, 33
  25. 2011, Detection of a monoclonal antibody therapy (ofatumumab) by serum protein and immunofixation electrophoresis, Br J Haematol, 155, 123, 10.1111/j.1365-2141.2011.08644.x · DOI
  26. 2009, Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma, Leukemia, 23, 3, 10.1038/leu.2008.291 · DOI · Paper page
  27. 2014, International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, Lancet Oncol, 15, e538, 10.1016/S1470-2045(14)70442-5 · DOI · Paper page
  28. 2015, Clarification of the definition of complete response in multiple myeloma, Leukemia, 29, 2416, 10.1038/leu.2015.290 · DOI · Paper page
  29. Elotuzumab: serum protein electrophoresis and immunofixation interference with clinical assessment of M-protein response in relapsed/refractory multiple myeloma (RRMM)
  30. 1998, Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation, Blood, 91, 3518, 10.1182/blood.V91.9.3518 · DOI
  31. 2010, Interference of monoclonal antibody therapies with serum protein electrophoresis tests, Clin Chem, 56, 1897, 10.1373/clinchem.2010.152116 · DOI · Paper page
  32. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79
  33. 2010, Interference of monoclonal antibody therapies with serum protein electrophoresis tests, Clin Chem, 56, 1897, 10.1373/clinchem.2010.152116 · DOI · Paper page
  34. 2011, Detection of a monoclonal antibody therapy (ofatumumab) by serum protein and immunofixation electrophoresis, Br J Haematol, 155, 123, 10.1111/j.1365-2141.2011.08644.x · DOI

Cited by

See all 124

Metadata

Authors
McCudden, C., Axel, A. E., Slaets, D., Dejoie, T., Clemens, P. L., Frans, S., Bald, J., Plesner, T., Jacobs, J. F. M., van de Donk, N. W. C. J., Moreau, P., Schecter, J. M., Ahmadi, T., & Sasser, A. K.
Venue
Clinical Chemistry and Laboratory Medicine (CCLM)
Published
2016-01-01
Volume
54
Issue
6
Pages
1095-104
ISSN
  • 1434-6621 (ISSN-L)
  • 1437-4331
OpenAlex
W2325601336
Cited by
124
References
10
FWCI
16.59
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference. https://app.cochat.ai/papers/10.1515/cclm-2015-1031
The paper
McCudden, C., Axel, A. E., Slaets, D., Dejoie, T., Clemens, P. L., Frans, S., Bald, J., Plesner, T., Jacobs, J. F. M., van de Donk, N. W. C. J., Moreau, P., Schecter, J. M., Ahmadi, T., & Sasser, A. K. (2016). Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference. Clinical Chemistry and Laboratory Medicine (CCLM). https://doi.org/10.1515/cclm-2015-1031

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.